Multibagger pharma stock: Shares of Welcure Drugs & Pharmaceuticals Ltd surged 5 per cent on Wednesday, hitting the upper circuit limit for the day, after the company reported robust financial results for the April–June quarter of FY2025-26.The stock climbed from its previous close of Rs 10.11 to Rs 10.61, marking a 4.95 per cent gain on the BSE. With this, the company’s market capitalization has risen to approximately Rs 114 crore. Over the past 52 weeks, the share has traded between Rs 6.40 and Rs 15.89.The pharma stock has delivered multibagger returns in past 2 years. As per BSE data, the stock gains more than 177 per cent in two years and up 697 per cent in last 5 years.Strong Q1 performance boosts investor sentimentWelcure Drugs on Tuesday announced a net profit of Rs 23.29 crore for the first quarter of FY26, significantly up from Rs 2.5 crore in the March 2025 quarter. The company’s revenue from operations also jumped sharply to Rs 299.91 crore in Q1FY26, compared to Rs 21.21 crore in the previous quarter.The company did not disclose the revenue figures for the corresponding June quarter of the previous fiscal year (FY25).In an exchange filing, the company said: “The strong financial performance in Q1FY26 is a reflection of our business strategies, meticulous decisions, and our focused transition to a fee-based, asset-light model.”Big orders drive growthWelcure added that it had recently completed seven export-sourcing assignments worth Rs 299.91 crore, working as a procurement agent for international clients. This aligns with its new fee-based business model.Notably, the company had earlier secured a Rs 517 crore global sourcing mandate from Thailand-based Fortune Sagar Impex Company Limited, a move seen as a major breakthrough in its export business.About Welcure DrugsFounded in 1992, Welcure Drugs & Pharmaceuticals Ltd is a recognized Indian pharmaceutical firm that manufactures and markets a wide range of pharmaceutical formulations. The company has now shifted its focus toward asset-light export sourcing to enhance margins and scalability.(Disclaimer: The above article is meant for informational purposes only, and should not be considered as any investment advice. ET NOW DIGITAL suggests its readers/audience to consult their financial advisors before making any money related decisions.)
Multibagger pharma stock: Shares hit 5% upper circuit after Q1 results; 697% RETURNS in 5 yrs
